"Anticholesteremic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances used to lower plasma CHOLESTEROL levels.
| Descriptor ID |
D000924
|
| MeSH Number(s) |
D27.505.519.186.071.202 D27.505.954.557.500.202
|
| Concept/Terms |
Anticholesteremic Agents- Anticholesteremic Agents
- Agents, Anticholesteremic
- Inhibitors, Cholesterol
- Cholesterol Inhibitors
- Anticholesteremic Drugs
- Drugs, Anticholesteremic
- Anticholesteremics
|
Below are MeSH descriptors whose meaning is more general than "Anticholesteremic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anticholesteremic Agents".
This graph shows the total number of publications written about "Anticholesteremic Agents" by people in this website by year, and whether "Anticholesteremic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 1 | 3 |
| 1997 | 6 | 0 | 6 |
| 1998 | 2 | 2 | 4 |
| 1999 | 2 | 0 | 2 |
| 2000 | 6 | 1 | 7 |
| 2001 | 8 | 1 | 9 |
| 2002 | 3 | 3 | 6 |
| 2003 | 6 | 1 | 7 |
| 2004 | 4 | 2 | 6 |
| 2005 | 3 | 1 | 4 |
| 2006 | 6 | 1 | 7 |
| 2007 | 2 | 2 | 4 |
| 2008 | 10 | 4 | 14 |
| 2009 | 5 | 2 | 7 |
| 2010 | 2 | 1 | 3 |
| 2011 | 6 | 0 | 6 |
| 2012 | 5 | 0 | 5 |
| 2013 | 4 | 2 | 6 |
| 2014 | 3 | 0 | 3 |
| 2015 | 3 | 1 | 4 |
| 2016 | 3 | 0 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 7 | 1 | 8 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 1 | 2 |
| 2023 | 2 | 0 | 2 |
| 2024 | 2 | 2 | 4 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anticholesteremic Agents" by people in Profiles.
-
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025 05 17; 405(10491):1757-1768.
-
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trials. Pharmacol Res Perspect. 2024 Dec; 12(6):e70010.
-
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity. Curr Opin Lipidol. 2024 Dec 01; 35(6):303-309.
-
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib. J Clin Pharmacol. 2024 Sep; 64(9):1150-1164.
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
-
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2023 10; 43(10):e404-e442.
-
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
-
Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. J Clin Lipidol. 2022 Jul-Aug; 16(4):538-543.
-
Targeting PCSK9 inhibitors to those who will benefit most. Lancet Diabetes Endocrinol. 2022 05; 10(5):301-303.
-
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224.